Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 2/20 | 0.64 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.64 |
| ▸ | STS | P08842 | 2/20 | 0.61 |
| ▸ | MIF | P14174 | 4/20 | 0.54 |
| ▸ | FLT3 | P36888 | 2/20 | 0.54 |
| ▸ | GSK3B | P49841 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | SNCA | P37840 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.50 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA5A | P35218 | 1/20 | 0.47 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23557835 | 0.87 | HSD17B1 (0.76) | HSD17B1HSD17B2STSMIFFLT3 | |
| SCHEMBL31574333 | 0.85 | HSD17B1 (0.74) | HSD17B1HSD17B2STSMIFFLT3 | |
| SCHEMBL14152110 | 0.83 | HSD17B1 (0.71) | HSD17B1HSD17B2MIFFLT3GSK3B | |
| SCHEMBL23557701 | 0.81 | HSD17B1 (0.64) | HSD17B1HSD17B2STSMIFFLT3 | |
| SCHEMBL23557829 | 0.81 | HSD17B1 (0.64) | HSD17B1HSD17B2STSMIFFLT3 | |
| SCHEMBL23557700 | 0.81 | HSD17B1 (0.64) | HSD17B1HSD17B2STSMIFMAPT | |
| SCHEMBL23528103 | 0.81 | HSD17B1 (0.64) | HSD17B1HSD17B2STSMIFFLT3 | |
| SCHEMBL23557617 | 0.79 | CYP1B1 (0.75) | HSD17B1HSD17B2STSMIFMAPT | |
| SCHEMBL23557658 | 0.79 | HSD17B1 (0.65) | HSD17B1HSD17B2MIFFLT3GSK3B | |
| SCHEMBL23086229 | 0.79 | HSD17B1 (0.74) | HSD17B1HSD17B2MIFMAPTSNCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3790868-B1 | SULFAMATE DERIVATIVES OF 4-(1-PHENYL-1H-[1,2,3]TRIAZOL-4-YL)-PHENOL, DERIVATIVES OF 4-(1-PHENYL-1H-[1,2,3]TRIAZOL-4-YL)-PHENOL, THEIR MEDICAL USE AND THE METHOD OF OBTAINING 4-(1-PHENYL-1H-[1,2,3]TRIAZOL-4-YL)-PHENYL SULFAMATE DERIVATIVES | POLITECHNIKA GDANSKA (PL) | 2023-01-11 | — | — | EP | disclosed |
| US-20210188785-A1 | SULFAMATE DERIVATIVES OF 4-(1-PHENYL-1H-[1,2,3]TRIAZOL-4-YL)-PHENOL, DERIVATIVES OF 4-(1-PHENYL-1H-[1,2,3]TRIAZOL-4-YL)-PHENOL, THEIR MEDICAL USE AND THE METHOD OF OBTAINING 4-(1-PHENYL-1H-[1,2,3]TRIAZOL-4-YL)-PHENYL SULFAMATE DERIVATIVES | POLITECHNIKA GDANSKA (PL) | 2021-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188785-A1 | SULFAMATE DERIVATIVES OF 4-(1-PHENYL-1H-[1,2,3]TRIAZOL-4-YL)-PHENOL, DERIVATIVES OF 4-(1-PHENYL-1H-[1,2,3]TRIAZOL-4-YL)-PHENOL, THEIR MEDICAL USE AND THE METHOD OF OBTAINING 4-(1-PHENYL-1H-[1,2,3]TRIAZOL-4-YL)-PHENYL SULFAMATE DERIVATIVES | SULT1E1, SULT2A1, SULT1A1 | HSD17B1 136/4885HSD17B2 221/4885STS 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.